Physiological phenotype and vulnerability in Parkinson's disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 7, 2012, Pages

  James Surmeier, D ^a   Guzman, Jaime N ^a   Sanchez, Javier ^a   Schumacker, Paul T ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; ISRADIPINE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; THIOREDOXIN 1; UBIDECARENONE; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; DOPAMINE; ION; MITOCHONDRIAL DNA;

AGING; CALCIUM SIGNALING; CALCIUM TRANSPORT; DOWN REGULATION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC REGULATION; HETEROZYGOSITY; HUMAN; MEMBRANE STEADY POTENTIAL; MITOCHONDRIAL DYNAMICS; MITOCHONDRIAL GENETICS; MITOCHONDRIAL RESPIRATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; RESPIRATORY CHAIN; REVIEW; SYNAPTIC TRANSMISSION; VENTRAL TEGMENTUM; ACTION POTENTIAL; ANIMAL; BIOSYNTHESIS; DISEASE PREDISPOSITION; ENERGY METABOLISM; GENE DELETION; GENETICS; METABOLISM; MITOCHONDRION; NERVE CELL; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; SUBSTANTIA NIGRA;

ACTION POTENTIALS; AGING; ANIMALS; CALCIUM CHANNELS, L-TYPE; DIHYDROPYRIDINES; DISEASE SUSCEPTIBILITY; DNA, MITOCHONDRIAL; DOPAMINE; ENERGY METABOLISM; HUMANS; IONS; MITOCHONDRIA; NEURONS; PARKINSON DISEASE; PHENOTYPE; REACTIVE OXYGEN SPECIES; SEQUENCE DELETION; SUBSTANTIA NIGRA;

EID: 84886687133     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a009290     Document Type: Review

References (180)

1. Aguilaniu H, Durieux J, Dillin A. 2005. Metabolism, ubiquinone synthesis, and longevity. Genes Dev 19: 2399-2406.
2. Aston-Jones G. 2005. Brain structures and receptors involved in alertness. Sleep Med 6: S3-S7.
3. Atherton JF, Bevan MD. 2005. Ionic mechanisms underlying autonomous action potential generation in the somata and dendrites of GABAergic substantia nigra pars reticulata neurons in vitro. J Neurosci 25: 8272-8281.
4. Augustine GJ, Santamaria F, Tanaka K. 2003. Local calcium signaling in neurons. Neuron 40: 331-346.
5. 2+ store in the plasticity of central neurons. Trends Pharmacol Sci 27: 78-84.
6. Baris OR, Klose A, Kloepper JE, Weiland D, Neuhaus JF, Schauen M, Wille A, Muller A, Merkwirth C, Langer T, et al. 2011. The mitochondrial electron transport chain is dispensable for proliferation and differentiation of epidermal progenitor cells. Stem Cells 29: 1459-1468.
7. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, van der Mey A, Taschner PE, Rubinstein WS, Myers EN, et al. 2000. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851.
8. Beal MF. 1995. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366.
9. Beal MF, Matthews RT, Tieleman A, Shults CW. 1998. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2, 3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res 783: 109-114.
10. Bean BP. 1984. Nitrendipine block of cardiac calcium channels: High-affinity binding to the inactivated state. Proc Natl Acad Sci 81: 6388-6392.
11. Bean BP. 2007. The action potential in mammalian central neurons. Nat Rev Neurosci 8: 451-465.
12. Becker C, Jick SS, Meier CR. 2008. Use of antihypertensives and the risk of Parkinson disease. Neurology 70: 1438-1444.
13. Beckman KB, Ames BN. 1998. The free radical theory of aging matures. Physiol Rev 78: 547-581.
14. Belal C, Ameli NJ, El Kommos A, Bezalel S, Al'khafaji AM, Mughal MR, MattsonMP, Kyriazis GA, Tyrberg B, Chan SL. 2011. The homocysteine-inducible endoplasmic reticulum (ER) stress protein Herp counteracts mutant α-synuclein-induced ER stress via the homeostatic regulation of ER-resident calcium release channel proteins. Hum Mol Genet 21: 963-977.
15. Belzunegui S, San Sebastian W, Garrido-Gil P, Izal-Azcarate A, Vazquez-Claverie M, Lopez B, Marcilla I, Lanciego JL, Luquin MR. 2007. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 61: 1006-1012.
16. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al. 2006. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 38: 515-517.
17. Berg D, Niwar M, Maass S, Zimprich A, Moller JC, Wuellner U, Schmitz-HubschT, Klein C, Tan EK, Schols L, et al. 2005. α-Synuclein and Parkinson's disease: Implications from the screening of more than 1, 900 patients. Mov Disord 20: 1191-1194.
18. Berridge MJ. 2002. The endoplasmic reticulum: A multifunctional signaling organelle. Cell Calcium 32: 235-249.
19. Boldogh IR, Pon LA. 2007. Mitochondria on the move. Trends Cell Biol 17: 502-510.
20. Bonci A, Grillner P, Mercuri NB, Bernardi G. 1998. L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. J Neurosci 18: 6693-6703.
21. Bosco DA, LaVoie MJ, Petsko GA, Ringe D. 2011. Proteostasis and movement disorders: Parkinson's disease and amyotrophic lateral sclerosis. Cold Spring Harb Perspect Biol 3: a007500.
22. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24: 197-211.
23. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. 2004. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 318: 121-134.
24. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, Parker N. 2004a. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37: 755-767.
25. Brand MD, Buckingham JA, Esteves TC, Green K, Lambert AJ, Miwa S, MurphyMP, Pakay JL, Talbot DA, Echtay KS. 2004b. Mitochondrial superoxide and aging: Uncoupling-protein activity and superoxide production. Biochem Soc Symp 71: 203-213.
26. 2+ conductance. Synapse 1: 582-588.
27. 2+ transfer to mitochondria. Cell 142: 270-283.
28. Chan JY, Chan SH. 1989. Passive electrical properties of spontaneously active neurons in the nucleus reticularis gigantocellularis of the cat. Neurosci Lett 97: 169-174.
29. Chan CS, Shigemoto R, Mercer JN, Surmeier DJ. 2004. HCN2 and HCN1 channels govern the regularity of autonomous pacemaking and synaptic resetting in globus pallidus neurons. J Neurosci 24: 9921-9932.
30. Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. 2007. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 447: 1081-1086.
31. Chan CS, Glajch KE, Gertler TS, Guzman JN, Mercer JN, Lewis AS, Goldberg AB, Tkatch T, Shigemoto R, Fleming SM, et al. 2011. HCN channelopathy in external globus pallidus neurons in models of Parkinson's disease. Nat Neurosci 14: 85-92.
32. 2+-evoked activation of p38α MAPK and JNK1. Toxicology 262: 199-206.
33. 2+ diffusion. J Neurosci 26: 12127-12136.
34. Choi SW, Gerencser AA, Lee DW, Rajagopalan S, Nicholls DG, Andersen JK, Brand MD. 2011. Intrinsic bioenergetic properties and stress sensitivity of dopaminergic synaptosomes. J Neurosci 31: 4524-4534.
35. Clapham DE. 2007. Calcium signaling. Cell 131: 1047-1058.
36. Commoner B, Townsend J, Pake GE. 1954. Free radicals in biological materials. Nature 174: 689-691.
37. Cookson MR. 2010. Unravelling the role of defective genes. Prog Brain Res 183: 43-57.
38. Cookson MR, Bandmann O. 2010. Parkinson's disease: Insights from pathways. Hum Mol Genet 19: R21-R27.
39. Csordas G, Renken C, Varnai P, Walter L, Weaver D, Buttle KF, Balla T, MannellaCA, Hajnoczky G. 2006. Structural and functional features and significance of the physical linkage between ER and mitochondria. J Cell Biol 174: 915-921.
40. 2+channels contributes to the irregular firing of dopamine neurons in neonatal rats. J Neurosci 24: 11079-11087.
41. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122: 1437-1448.
42. Dawson TM, Dawson VL. 2003a. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302: 819-822.
43. Dawson TM, Dawson VL. 2003b. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 111: 145-151.
44. de Brito OM, Scorrano L. 2008. Mitofusin 2 tethers endoplasmic reticulum to mitochondria. Nature 456: 605-610.
45. de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. 2004. Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study. Neurology 63: 1240-1244.
46. Del Tredici K, Braak H. 2004. Idiopathic Parkinson's disease: Staging an α-synucleinopathy with a predictable pathoanatomy. In Molecular mechanisms of Parkinson's disease (ed. Kahle PJ, Haas C), pp. 1-32. Landes Bioscience, Georgetown, TX.
47. Denton RM, McCormack JG. 1986. The calcium sensitive dehydrogenases of vertebrate mitochondria. Cell Calcium 7: 377-386.
48. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA. 1997. Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON Collaborative Study. European community concerted action on the epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 62: 10-15.
49. De Stefani D, Raffaello A, Teardo E, Szabo I, Rizzuto R. 2011. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476: 336-340.
50. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ. 2010. Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67: 294-307.
51. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, KieburtzK, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, et al. 2007. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68: 384-386.
52. Durieux J, Wolff S, Dillin A. 2011. The cell-non-autonomous nature of electron transport chain-mediated longevity. Cell 144: 79-91.
53. Eisenberg MJ, Brox A, Bestawros AN. 2004. Calcium channel blockers: An update. Am J Med 116: 35-43.
54. Ekstrand MI, Terzioglu M, Galter D, Zhu S, Hofstetter C, Lindqvist E, Thams S, Bergstrand A, Hansson FS, Trifunovic A, et al. 2007. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proc Natl Acad Sci 104: 1325-1330.
55. Esteves AR, Arduino DM, Swerdlow RH, Oliveira CR, Cardoso SM. 2010. Microtubule depolymerization potentiates α-synuclein oligomerization. Front Aging Neurosci 1: 5.
56. Esteves AR, Arduino DM, Silva DF, Oliveira CR, Cardoso SM. 2011. Mitochondrial dysfunction: The road to α-synuclein oligomerization in PD. Parkinson's Dis 2011: 693761.
57. Fahn S. 2005. Does levodopa slow or hasten the rate of progression of Parkinson's disease? J Neurol 252: IV37-IV42.
58. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404: 394-398.
59. Fitton A, Benfield P. 1990. Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs 40: 31-74.
60. Foehring RC, Zhang XF, Lee JC, Callaway JC. 2009. Endogenous calcium buffering capacity of substantia nigral dopamine neurons. J Neurophysiol 102: 2326-2333.
61. Fortin DL, Nemani VM, Nakamura K, Edwards RH. 2010. The behavior of α-synuclein in neurons. Mov Disord 25: S21-S26.
62. Gerfen CR, Surmeier DJ. 2011. Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34: 441-466.
63. German DC, Manaye KF, Sonsalla PK, Brooks BA. 1992a. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: Sparing of calbindin-D28k-containing cells. Ann NY Acad Sci 648: 42-62.
64. German DC, Manaye KF, White CL III., Woodward DJ, McIntire DD, Smith WK, Kalaria RN, Mann DM. 1992b. Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32: 667-676.
65. Glaser CB, Yamin G, Uversky VN, Fink AL. 2005. Methionine oxidation, α-synuclein and Parkinson's disease. Biochim Biophys Acta 1703: 157-169.
66. Gomez-Tortosa E, Sanders JL, Newell K, Hyman BT. 2001. Cortical neurons expressing calcium binding proteins are spared in dementia with Lewy bodies. Acta Neuropathol 101: 36-42.
67. Greenamyre JT, Hastings TG. 2004. Biomedicine. Parkinson's-Divergent causes, convergent mechanisms. Science 304: 1120-1122.
68. Areceptor subunits in relation to rat striatopallidal and pallidopallidal synapses. Eur J Neurosci 33: 868-878.
69. Gubitz AK, Gwinn K. 2009. Mining the genome for susceptibility to complex neurological disorders. Curr Mol Med 9: 801-813.
70. Guzman JN, Sanchez-Padilla J, Chan CS, Surmeier DJ. 2009. Robust pacemaking in substantia nigra dopaminergic neurons. J Neurosci 29: 11011-11019.
71. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, SchumackerPT, Surmeier DJ. 2010. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468: 696-700.
72. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT. 2008. Loss of the SdhB, but not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28: 718-731.
73. Hanson GT, Aggeler R, Oglesbee D, Cannon M, Capaldi RA, Tsien RY, Remington SJ. 2004. Investigating mitochondrial redox potential with redox-sensitive green fluorescent protein indicators. J Biol Chem 279: 13044-13053.
74. Hansson A, Hance N, Dufour E, Rantanen A, Hultenby K, Clayton DA, Wibom R, Larsson NG. 2004. A switch in metabolism precedes increased mitochondrial biogenesis in respiratory chain-deficient mouse hearts. Proc Natl Acad Sci 101: 3136-3141.
75. Harman D. 1956. Aging: A theory based on free radical and radiation chemistry. J Gerontol 11: 298-300.
76. Hayashi T, Rizzuto R, Hajnoczky G, Su TP. 2009. MAM: More than just a housekeeper. Trends Cell Biol 19: 81-88.
77. 2+ signaling in human neuroblastoma (SH-SY5Y) cells. J Neurochem 111: 1192-1201.
78. Hirsch EC, Hunot S. 2009. Neuroinflammation in Parkinson's disease: A target for neuroprotection? Lancet Neurol 8: 382-397.
79. Holmgren A, Sengupta R. 2010. The use of thiols by ribonucleotide reductase. Free Radic Biol Med 49: 1617-1628.
80. Hornykiewicz O. 1966. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18: 925-964.
81. Huisman E, Uylings HB, Hoogland PV. 2008. Gender-related changes in increase of dopaminergic neurons in the olfactory bulb of Parkinson's disease patients. Mov Disord 23: 1407-1413.
82. Ilijic E, Guzman JN, Surmeier DJ. 2011. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 43: 364-371.
83. Ito H, Goto S, Sakamoto S, Hirano A. 1992. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann Neurol 32: 543-550.
84. Jang YC, Remmen VH. 2009. The mitochondrial theory of aging: Insight from transgenic and knockout mouse models. Exp Gerontol 44: 256-260.
85. Jang YC, Perez VI, Song W, Lustgarten MS, Salmon AB, Mele J, Qi W, Liu Y, LiangH, Chaudhuri A, et al. 2009. Overexpression of Mn superoxide dismutase does not increase life span in mice. J Gerontol A Biol Sci Med Sci 64: 1114-1125.
86. Jensen PK. 1966a. Antimycin-insensitive oxidation of succinate and reduced nicotinamide-adenine dinucleotide in electron-transport particles. I. pH dependency and hydrogen peroxide formation. Biochim Biophys Acta 122: 157-166.
87. Jensen PK. 1966b. Antimycin-insensitive oxidation of succinate and reduced nicotinamide-adenine dinucleotide in electron-transport particles. II. Steroid effects. Biochim Biophys Acta 122: 167-174.
88. Jouaville LS, Pinton P, Bastianutto C, Rutter GA, Rizzuto R. 1999. Regulation of mitochondrial ATP synthesis by calcium: Evidence for a long-term metabolic priming. Proc Natl Acad Sci 96: 13807-13812.
89. Kirichok Y, Krapivinsky G, Clapham DE. 2004. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 427: 360-364.
90. Kish SJ, Shannak K, Hornykiewicz O. 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 318: 876-880.
91. Korshunov SS, Skulachev VP, Starkov AA. 1997. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett 416: 15-18.
92. 2+ channels activating at negative voltages. J Biol Chem 276: 22100-22106.
93. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K. 2006. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat Genet 38: 518-520.
94. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, EpplenJT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
95. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, et al. 2005. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481-484.
96. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1996. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 741: 185-196.
97. Lee CR, Tepper JM. 2007. Morphological and physiological properties of parvalbumin-and calretinin-containing γ-aminobutyric acidergic neurons in the substantia nigra. J Comp Neurol 500: 958-972.
98. Lee I, Bender E, Arnold S, Kadenbach B. 2001. New control of mitochondrial membrane potential and ROS formation-A hypothesis. Biol Chem 382: 1629-1636.
99. Lin J, Wu H, Tarr PT, Zhang CY, Wu Z, Boss O, Michael LF, Puigserver P, IsotaniE, Olson EN, et al. 2002. Transcriptional co-activator PGC-1α drives the formation of slow-twitch muscle fibres. Nature 418: 797-801.
100. Lowe R, Pountney DL, Jensen PH, Gai WP, Voelcker NH. 2004. Calcium(II) selectively induces α-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci 13: 3245-3252.
101. Magyar K, Szende B. 2004. (-)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. Neurotoxicology 25: 233-242.
102. Mannhold R, Rekker RF, Sonntag C, ter Laak AM, Dross K, Polymeropoulos EE. 1995. Comparative evaluation of the predictive power of calculation procedures for molecular lipophilicity. J Pharm Sci 84: 1410-1419.
103. Matsuda W, Furuta T, Nakamura KC, Hioki H, Fujiyama F, Arai R, Kaneko T. 2009. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J Neurosci 29: 444-453.
104. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. 1999. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157: 142-149.
105. Mattson MP. 2007. Calcium and neurodegeneration. Aging Cell 6: 337-350.
106. Matzuk MM, Saper CB. 1985. Preservation of hypothalamic dopaminergic neurons in Parkinson's disease. Ann Neurol 18: 552-555.
107. McCann MJ, Rogers RC. 1990. Oxytocin excites gastric-related neurones in rat dorsal vagal complex. J Physiol 428: 95-108.
108. McCormack JG, Halestrap AP, Denton RM. 1990. Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70: 391-425.
109. McMahon HT, Nicholls DG. 1991. The bioenergetics of neurotransmitter release. Biochim Biophys Acta 1059: 243-264.
110. Medvedev GS, Wilson CJ, Callaway JC, Kopell N. 2003. Dendritic synchrony and transient dynamics in a coupled oscillator model of the dopaminergic neuron. J Comput Neurosci 15: 53-69.
111. Mercer JN, Chan CS, Tkatch T, Held J, Surmeier DJ. 2007. Nav1. 6 sodium channels are critical to pacemaking and fast spiking in globus pallidus neurons. J Neurosci 27: 13552-13566.
112. 2+ entry through basal membrane patch. Cell 88: 49-55.
113. 2+ mobilization in dopamine neurons. J Neurosci 23: 149-157.
114. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D. 2009. Interplay between cytosolic dopamine, calcium, and α-synuclein causes selective death of substantia nigra neurons. Neuron 62: 218-229.
115. 2+ signaling. Antioxid Redox Signal 14: 1225-1235.
116. Murphy MP. 2009. How mitochondria produce reactive oxygen species. Biochem J 417: 1-13.
117. Nath S, Goodwin J, Engelborghs Y, Pountney DL. 2011. Raised calcium promotes α-synuclein aggregate formation. Mol Cell Neurosci 46: 516-526.
118. 2+ conductances in guinea-pig substantia nigra pars compacta neurones. J Physiol 466: 727-747.
119. Nicholls D. 2002. Mitochondrial bioenergetics, aging, and aging-related disease. Sci Aging Knowledge Environ 2002: e12.
120. Nicholls DG, Johnson-Cadwell L, Vesce S, Jekabsons M, Yadava N. 2007. Bioenergetics of mitochondria in cultured neurons and their role in glutamate excitotoxicity. J Neurosci Res 85: 3206-3212.
121. 2+ binding to α-synuclein regulates ligand binding and oligomerization. J Biol Chem 276: 22680-22684.
122. Paladini CA, Beckstead MJ, Weinshenker D. 2007. Electrophysiological properties of catecholaminergic neurons in the norepinephrine-deficient mouse. Neuroscience 144: 1067-1074.
123. 2+ movements and equilibration. EMBO J 19: 5729-5739.
124. Park MK, Choi YM, Kang YK, Petersen OH. 2008. The endoplasmic reticulum as an integrator of multiple dendritic events. Neuroscientist 14: 68-77.
125. Pearl R. 1928. The rate of living, being an account of some experimental studies on the biology of life duration. Alfred A Knopf, New York.
126. Perez VI, Lew CM, Cortez LA, Webb CR, Rodriguez M, Liu Y, Qi W, Li Y, Chaudhuri A, Van Remmen H, et al. 2008. Thioredoxin 2 haploinsufficiency in mice results in impaired mitochondrial function and increased oxidative stress. Free Radic Biol Med 44: 882-892.
127. Perez VI, Bokov A, Van Remmen H, Mele J, Ran Q, Ikeno Y, Richardson A. 2009. Is the oxidative stress theory of aging dead? Biochim Biophys Acta 1790: 1005-1014.
128. Perez VI, Cortez LA, Lew CM, Rodriguez M, Webb CR, Van Remmen H, Chaudhuri A, Qi W, Lee S, Bokov A, et al. 2011. Thioredoxin 1 overexpression extends mainly the earlier part of life span in mice. J Gerontol A Biol Sci Med Sci 66: 1286-1299.
129. Pignatelli A, Kobayashi K, Okano H, Belluzzi O. 2005. Functional properties of dopaminergic neurones in the mouse olfactory bulb. J Physiol 564: 501-514.
130. Pignatelli A, Ackman JB, Vigetti D, Beltrami AP, Zucchini S, Belluzzi O. 2009. A potential reservoir of immature dopaminergic replacement neurons in the adult mammalian olfactory bulb. Pflugers Arch 457: 899-915.
131. + channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 7: 809-814.
132. 2+-dependent slow afterdepolarization in nigral dopamine neurons. J Neurophysiol 81: 977-984.
133. Pizzo P, Pozzan T. 2007. Mitochondria-endoplasmic reticulum choreography: Structure and signaling dynamics. Trends Cell Biol 17: 511-517.
134. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, et al. 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
135. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. 2006. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66: 845-851.
136. Przedborski S, Vila M. 2003. The 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model: A tool to explore the pathogenesis of Parkinson's disease. Ann NY Acad Sci 991: 189-198.
137. Przedborski S, Tieu K, Perier C, Vila M. 2004. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J Bioenerg Biomembr 36: 375-379.
138. Puopolo M, Bean BP, Raviola E. 2005. Spontaneous activity of isolated dopaminergic periglomerular cells of the main olfactory bulb. J Neurophysiol 94: 3618-3627.
139. Puopolo M, Raviola E, Bean BP. 2007. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. J Neurosci 27: 645-656.
140. 2+ selectivity, drives pacemaker activity and amplifies bursts in nigral dopamine neurons. J Neurosci 29: 15414-15419.
141. 2 signaling. Antioxid Redox Signal 14: 459-468.
142. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. 2010. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 67: 600-606.
143. 2+: Molecular determinants and functional consequences. Physiol Rev 86: 369-408.
144. Romo R, Schultz W. 1990. Dopamine neurons of the monkey midbrain: Contingencies of responses to active touch during self-initiated arm movements. J Neurophysiol 63: 592-606.
145. Rose CR, Konnerth A. 2001. Stores not just for storage: Intracellular calcium release and synaptic plasticity. Neuron 31: 519-522.
146. Saper CB, Sorrentino DM, German DC, de Lacalle S. 1991. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann Neurol 29: 577-584.
147. Schapira AH. 2011. Mitochondrial pathology in Parkinson's disease. Mt Sinai J Med 78: 872-881.
148. Scholze A, Plant TD, Dolphin AC, Nurnberg B. 2001. Functional expression and characterization of a voltage-gated CaV1. 3 (α1D) calcium channel subunit from an insulin-secreting cell line. Mol Endocrinol 15: 1211-1221.
149. Schriner SE, Linford NJ, Martin GM, Treuting P, Ogburn CE, Emond M, CoskunPE, Ladiges W, Wolf N, Van Remmen H, et al. 2005. Extension of murine life span by overexpression of catalase targeted to mitochondria. Science 308: 1909-1911.
150. Schwyn RC, Fox CA. 1974. The primate substantia nigra: A Golgi and electron microscopic study. J Hirnforsch 15: 95-126.
151. Serafin M, Khateb A, Muhlethaler M. 1990. Opiates inhibit pedunculopontine neurones in guinea pig brainstem slices. Neurosci Lett 119: 125-128.
152. Shastry BS. 2003. Neurodegenerative disorders of protein aggregation. Neurochem Int 43: 1-7.
153. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, Shimizu N, Iwai K, Chiba T, Tanaka K, et al. 2000. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25: 302-305.
154. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM. 2011. PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144: 689-702.
155. Shults CW, Haas RH, Passov D, Beal MF. 1997. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann Neurol 42: 261-264.
156. Simon KC, Gao X, Chen H, Schwarzschild MA, Ascherio A. 2010. Calcium channel blocker use and risk of Parkinson's disease. Mov Disord 25: 1818-1822.
157. Sinnegger-Brauns MJ, Huber IG, Koschak A, Wild C, Obermair GJ, Einzinger U, Hoda JC, Sartori SB, Striessnig J. 2009. Expression and 1, 4-dihydropyridine-binding properties of brain L-type calcium channel isoforms. Mol Pharmacol 75: 407-414.
158. Smith RA, Murphy MP. 2011. Mitochondria-targeted antioxidants as therapies. Discov Med 11: 106-114.
159. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. 1998. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci 95: 6469-6473.
160. Stevens DR, Haas HL. 1996. Calcium-dependent prepotentials contribute to spontaneous activity in rat tuberomammillary neurons. J Physiol 493: 747-754.
161. Sulzer D, Zecca L. 2000. Intraneuronal dopamine-quinone synthesis: A review. Neurotox Res 1: 181-195.
162. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA. 2010. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal 14: 1289-1301.
163. Taddese A, Bean BP. 2002. Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. Neuron 33: 587-600.
164. Tamamizu-Kato S, Kosaraju MG, Kato H, Raussens V, Ruysschaert JM, Narayanaswami V. 2006. Calcium-triggered membrane interaction of the α-synuclein acidic tail. Biochemistry 45: 10947-10956.
165. Trancikova A, Tsika E, Moore DJ. 2011. Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal 16: 896-919.
166. Travagli RA, Gillis RA, Rossiter CD, Vicini S. 1991. Glutamate and GABA-mediated synaptic currents in neurons of the rat dorsal motor nucleus of the vagus. Am J Physiol 260: G531-G536.
167. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, et al. 2004. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417-423.
168. Van Remmen H, Ikeno Y, Hamilton M, Pahlavani M, Wolf N, Thorpe SR, Alderson NL, Baynes JW, Epstein CJ, Huang TT, et al. 2003. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics 16: 29-37.
169. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L. 2011. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol 10: 1015-1025.
170. Verkhratsky A. 2005. Physiology and pathophysiology of the calcium store in the endoplasmic reticulum of neurons. Physiol Rev 85: 201-279.
171. Vermulst M, Bielas JH, Kujoth GC, Ladiges WC, Rabinovitch PS, Prolla TA, LoebLA. 2007. Mitochondrial point mutations do not limit the natural lifespan of mice. Nat Genet 39: 540-543.
172. Vermulst M, Wanagat J, Kujoth GC, Bielas JH, Rabinovitch PS, Prolla TA, LoebLA. 2008. DNA deletions and clonal mutations drive premature aging in mitochondrial mutator mice. Nat Genet 40: 392-394.
173. m-Dependent and-independent production of reactive oxygen species by rat brain mitochondria. J Neurochem 79: 266-277.
174. Wallace DC. 2010. Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen 51: 440-450.
175. Wider C, Foroud T, Wszolek ZK. 2010. Clinical implications of gene discovery in Parkinson's disease and parkinsonism. Mov Disord 25: S15-S20.
176. Williams JT, North RA, Shefner SA, Nishi S, Egan TM. 1984. Membrane properties of rat locus coeruleus neurones. Neuroscience 13: 137-156.
177. Wilson CJ, Callaway JC. 2000. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. J Neurophysiol 83: 3084-3100.
178. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. 1990. Relative sparing in Parkinson' disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res 526: 303-307.
179. Zara V, Conte L, Trumpower BL. 2007. Identification and characterization of cytochrome bc(1) subcomplexes in mitochondria from yeast with single and double deletions of genes encoding cytochrome bc(1) subunits. FEBS J 274: 4526-4539.
180. Zigmond MJ, Abercrombie ED, Stricker EM. 1990. Partial damage to nigrostriatal bundle: Compensatory changes and the action of L-dopa. J Neural Transm Suppl 29: 217-232.